

AMR Conference

The 2020 digital AMR Conference was an international forum to discuss AMR in the context of COVID-19 and beyond.

Each day covered a focus topic with LIVE sessions and high-level panels:

[Lessons learned from COVID-19](#) | [Business Models & Policy Incentives](#) | [Global Markets](#) | [Financing & Investing](#) | [Outlook & Policy Roadmap](#)

Registered participants have access to on-demand versions of all sessions.

[Day 1 | Monday, 24 August 2020](#) ▶

[Day 2 | Tuesday, 25 August 2020](#) ▲

Overall theme of the day: **Business Models & Policy Incentives**

Moderation:

- Isabelle Bekeredjian-Ding – Head of Department, Paul-Ehrlich Institut

Speakers:

- Claus Stie Kallesøe – CEO & Co-founder, [grit42](#)
- Dirk Bumann – Professor for Infection Biology, The Center for Molecular Life Sciences, [University of Basel](#)
- Dave Madge – Vice President, Research Service Division, [WuXi AppTec](#)
- Cuong Vuong, Director Bacteriology, [AiCuris](#)

Further reading tips:

- [Overview of Swiss research network NCCR AntiResist](#)
- European Biotechnology Magazine, 18 August: [Aicuris to launch AiCubator to fight AMR](#)
- By IMI AMR Accelerator & COMBINE project: [Call for preclinical and clinical data sets from the study of prevention or treatment of bacterial infections](#)
- Explore these AMR Stakeholder Guide profiles: [grit42](#), [University of Basel](#), [WuXi AppTec](#), [AiCuris](#)

11:15–12:15 CET

ENABLE: A public-private partnership for antibiotic development

This content has been restricted to logged in users only. Please [login](#) to view this content.

Speakers:

- Anders Karlén – ENABLE Coordinator, Uppsala University
- Jürgen Brem – Project Leader OU-ENABLE, Oxford University
- Francois Moreau – Scientific Director, Mutabilis
- Sven Hobbie – CEO & Co-founder, Juvabis

Further reading tips:

- Overview of ENABLE outcomes: [What we have achieved](#)
- [Juvabis](#) in the AMR Stakeholder Guide

Sponsored by:



Moderator:

- Erin Duffy – Chief of Research & Development, [CARB-X](#)

Speakers:

- Jonathan Butcher – Head of Business Development, [BioVersys AG](#)
- Cherif Bousselham – Senior Vice President, Head of Sales, EMEA, Accelerate Diagnostics Inc.
- Jean-Pierre Paccaud – Director of Business Development and Corporate Strategy, [GARDP](#)
- Kenneth Bradley – Global Head, Infectious Disease Discovery, Roche

Further reading tips:

- [Read the latest funding news by CARB-X](#)
 - Explore these AMR Stakeholder Guide profiles: [CARB-X](#), [BioVersys AG](#), [GARDP](#)
-

Sponsored by:



Moderator:

- Gökhan Batur – CEO, [Polyphor Ltd](#)

Speakers:

- Peter Beyer – Senior Advisor Department of Essential Medicines & Health Products, WHO
- Erin Duffy – Chief of Research & Development, [CARB-X](#)
- Holger Zimmermann – CEO, [AiCuris](#)

Further reading tips:

- ACS Infect. Dis. 2020, 12 June: By Peter Beyer & Sarah Paulin, WHO: [The Antibacterial Research and Development Pipeline Needs Urgent Solutions](#)
- Explore these AMR Stakeholder Guide profiles: [Polyphor Ltd](#), [CARB-X](#), [AiCuris](#)

16:30–17:45 CET

AMR pull incentives | Will COVID-19 speed up or slow down implementation?

This content has been restricted to logged in users only. Please [login](#) to view this content.

Moderator:

- Kathy Talkington, Director Health Programs, Pew Charitable Trust

Speakers:

- Suzanne Edwards – Programme Officer/Economist, [Global AMR R&D Hub](#)
- Kevin Outterson – Professor of Law & Executive Director, [CARB-X](#)
- Colm Leonard – Clinical Advisor/Consultant, NICE
- Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta

Further reading tips:

- Pew Trust: Take Action: Antibiotic resistance is a looming threat. [Urge Your Senators to act](#)
- Nature Magazine, 11 August: [Pharmaceutical firms commit US\\$1 billion to antibiotic development](#)
- Stat News, 12th August, by Kevin Outterson: [We need new antimicrobials to prevent the next infectious disease crisis](#)
- ACS Infect. Dis. 2020: Viewpoint, 12 June: By Wes Kim, The Pew Charitable Trust: [On the Road to Discovering Urgently Needed Antibiotics: So Close Yet So Far Away](#)
- Explore these AMR Stakeholder Guide profiles: [Global AMR R&D Hub](#), [CARB-X](#)

Moderator:

- Till Bachmann – Deputy Head of Infection Medicine and Personal chair of Molecular Diagnostics and Infection, University of Edinburgh

Speakers:

- Colm Leonard – Clinical Advisor/Consultant, NICE
- Philippe Cleuziat – Innovation Program Senior Director, bioMérieux, VALUE-Dx
- Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta
- Cecilia Ferreyra, Head of AMR Programme, FIND

Further reading tips:

- [Overview of Value-Dx project](#)
- [More info about the free technical workshops and support sessions provided by Longitude Prize SPRINT Programme](#), launched July 2020
- [FIND](#) in the AMR Stakeholder Guide

19:00–20:00 CET

Expert Campus | Diagnostics in clinical trial settings

This content has been restricted to logged in users only. Please [login](#) to view this content.

Supported by:

LONGITUDE PRIZE

Moderator:

- Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta

Speakers:

- Kwangmin Son – Co-founder & CEO, Phast Corp.
- Michael Lobritz – Translational Project Leader, Roche
- Laurenz Kellenberger, CSO, Basilea

Further reading tips:

- Learn more about diagnostics company PHAST Corp.: <https://phastdiagnostics.com> & <https://longitudeprize.org/teams/phast>
- By CARB-X & Longitude Prize; 16 June: [CARB-X AWARDS \\$3.2M TO LONGITUDE PRIZE CONTENDER, MODULE INNOVATIONS](#)
- By Longitude Prize, 21 May: [The long read: We must do better for UTI patients](#)

ALL DAY

Virtual 1:1 Partnering Meetings – [LOGIN HERE](#)

09:15–10:45 CET

Expert campus | Focus on tuberculosis*Supported by:*

This content has been restricted to logged in users only. Please [login](#) to view this content.

Moderation & Introduction:

- Santiago Ramón-García, Research & Development Agency of Aragon (ARAID) Foundation & Mycobacterial Genetics Group, Dept. of Microbiology, University of Zaragoza
- Ruben Hartkoorn – Institut Pasteur de Lille, INSERM

Speakers:

- Michel Pieren – Project Manager, [BioVersys AG](#), CH
- Florian Kloss – Head, [Hans Knöll Institute \(HKI\)](#), GER
- Michael Hoelscher – Network Coordinator, Ludwig-Maximilians-University Munich (LMU), GER

Further reading tips:

- Development of novel treatments to treat TB is in the focus of the [IMI AMR Accelerator](#) > Please find here more information about the ongoing projects: [ERA4TB](#), [TRIC-TB](#)
- [Updated WHO information on TB & Covid-19, 12 May](#)
Article by ERA4TB & Stop TB Partnership, 20 May: [The potential impact of the Covid-19 response on tuberculosis in high-burden countries: a modelling analysis](#)
- Harvard Medical School, 5 August: [New generation of drugs show early efficacy against drug-resistant TB](#)
- Press release by LMU Munich & Leibniz HKI, 19 Nov 2019: [New drug substance BTZ-043 is being tested on patients for the first time](#)
- [BioVersys AG](#) in the AMR Stakeholder Guide

Moderation:

- Anita Suresh – Head of Sequencing, FIND

Speakers:

- Courtney Maus – Scientific Director Life Sciences, BD
- Sebastian Dümcke – CEO, Clemedi AG
- Dessislava Tarlton, Programme Management Officer, molecular diagnostics and cervical cancer, Unitaid

Further reading tips:

- Overview of tuberculosis programme at [FIND](#)
- From the CEO of FIND, Catharina Boehme, 24 March: COVID-19: [a message of solidarity on World TB Day 2020](#)
- [See here for BD's global health site for tuberculosis](#)
- [Why is UNITAID investing in tuberculosis diagnostics](#)
- [FIND](#) in the AMR Stakeholder Guide

13:30–15:00 CET

Global markets | Why we need to think global to tackle AMR

This content has been restricted to logged in users only. Please [login](#) to view this content.

Moderator:

- Marc Lemonnier – Founding CEO, Antabio SAS

Speakers:

- Heiman Wertheim – Head of Clinical Microbiology Department, Radboud University Medical Center
- Anand Anandkumar – CEO, Bugworks
- Alexandra Cameron – Senior Technical Manager Strategy Team, UNITAID
- Bruce Altevogt, Vice President and Head External Medical Engagement, Hospital Business Unit, Pfizer

Further reading tips:

- [More information about the Open access global treatment guideline for antimicrobials](#), by Heiman Wertheim
- [Wellcome Trust and Pfizer launch surveillance program to combat growing threat of antimicrobial resistance in sub-saharan africa](#)
- [Unitaid is supporting the LONGEVITY project of University of Liverpool](#)
- [Unitaid deepens its commitment to fighting epidemics old and new, marks World Tuberculosis Day](#)
- [C-Camp has launched C-CAMP COVID-19 innovations deployment accelerator](#)
- [Life science incubator C-CAMP launches AMR accelerator programme to encourage antimicrobial resistance innovations](#), 14 August 2020

Moderator:

- Ron de Winter – Programme Manager European Projects, UMC Utrecht

Speakers:

- Seamus O'Brien – R&D Director, [GARDP](#)
- Tim Jinks – Head of Antibiotic Resistance Infections Program, Wellcome Trust
- Florence Séjourné – CEO, DaVolterra & President, [BEAM Alliance](#)
- Kamini Walia – Head of AMR, ICMR, Government of India

Further reading tips:

- More information about [European Clinical Research Alliance on Infectious Diseases](#)
- COMBACTE: [Combating bacterial resistance in Europe](#)
- By Wellcome Trust: [The growing crisis in antibiotic R&D: opportunities for G20 member action to support sustainable innovation](#) & further information on [WT's activities to fight against AMR](#)
- Enabling AMR-related Clinical Trials in India: [Network Exploratory Workshop](#)
- Latest news by GARDP can be found [here](#)
- Webinar recording by GARDP: [The challenges and opportunities for antimicrobial R&D in low- and middle-income countries](#) – India case study
- [Wellcome](#) and [GARDP](#) in the AMR Stakeholder Guide

17:45–18:30 CET

Regulatory perspective | Current status and the post-COVID outlook for antibiotic clinical trials & approvals

This content has been restricted to logged in users only. Please [login](#) to view this content.

Moderator:

- John Rex, Chief Medical Officer, F2G Ltd.

Speakers:

- Sumathi Nambiar – Director Division of Anti-Infective Products, Office of Infectious Diseases, FDA
- Marco Cavalieri – Head of Antiinfectives and Vaccines, Safety&Efficacy Sector, EMA

Further reading tips:

- Upcoming PACCARB Meeting: September 9-10, [2020 Virtual Public Meeting – Antimicrobial Resistance and COVID-19](#)
- [Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhoea](#), public workshop by FDA, NIAID and CDC
- [COVID-19: EMA sets up infrastructure for real-world monitoring of treatments and vaccines](#)
- [Launch of public consultation on joint network strategy to 2025](#), 6 July

ALL DAY

Virtual 1:1 Partnering Meetings – [LOGIN HERE](#)

Day 4 | Thursday, 27 August 2020

BEAM Alliance programme committee



Marc Gitzinger

CEO, BioVersys AG, CH & Vice
President Board, BEAM Alliance



Marc Lemonnier

Founding CEO, Antabio SAS



Deborah O'Neil

CEO, NovaBiotics Ltd & Board
Member, BEAM Alliance

